Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAF<sup>V600E</sup>
The investigation of novel EGFR and BRAF<sup>V600E</sup> dual inhibitors is intended to serve as targeted cancer treatment. Two sets of purine/pteridine-based derivatives were designed and synthesized as EGFR/BRAF<sup>V600E</sup> dual inhibitors. The majority of the compounds...
Saved in:
Main Authors: | Samar A. El-Kalyoubi (Author), Hesham A. M. Gomaa (Author), Elshimaa M. N. Abdelhafez (Author), Mohamed Ramadan (Author), Fatimah Agili (Author), Bahaa G. M. Youssif (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synthesis and Structure Determination of Substituted Thiazole Derivatives as EGFR/BRAF<sup>V600E</sup> Dual Inhibitors Endowed with Antiproliferative Activity
by: Lamya H. Al-Wahaibi, et al.
Published: (2023) -
Quinazolin-4-one/3-cyanopyridin-2-one Hybrids as Dual Inhibitors of EGFR and BRAF<sup>V600E</sup>: Design, Synthesis, and Antiproliferative Activity
by: Lamya H. Al-Wahaibi, et al.
Published: (2023) -
One-Pot Synthesis of 1-Thia-4-azaspiro[4.4/5]alkan-3-ones via Schiff Base: Design, Synthesis, and Apoptotic Antiproliferative Properties of Dual EGFR/BRAF<sup>V600E</sup> Inhibitors
by: Lamya H. Al-Wahaibi, et al.
Published: (2023) -
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF<sup>V600E</sup> Mutated Parent- and Vemurafenib-Resistant Melanoma
by: Yige Fu, et al.
Published: (2019) -
HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF<sup>V600E</sup> Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
by: Anna Lisa Furfaro, et al.
Published: (2022)